Kyntra Bio, Inc. (KYNB)

Kyntra Bio Statistics

Total Valuation

Kyntra Bio has a market cap or net worth of $37.30 million. The enterprise value is -$61.20 million.

Market Cap	37.30M
Enterprise Value	-61.20M

Important Dates

The next estimated earnings date is Monday, February 23, 2026.

Earnings Date	Feb 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Kyntra Bio has 4.05 million shares outstanding. The number of shares has increased by 1.55% in one year.

Current Share Class	4.05M
Shares Outstanding	4.05M
Shares Change (YoY)	+1.55%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	16.35%
Float	3.58M

Valuation Ratios

The trailing PE ratio is 0.17.

PE Ratio	0.17
Forward PE	n/a
PS Ratio	4.49
Forward PS	n/a
PB Ratio	2.13
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.11.

Current Ratio	3.71
Quick Ratio	3.56
Debt / Equity	1.11
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.91

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-18.42%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-58.55%
Revenue Per Employee	$36,880
Profits Per Employee	$958,462
Employee Count	225
Asset Turnover	0.04
Inventory Turnover	2.78

Taxes

Income Tax	-88,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.33% in the last 52 weeks. The beta is 0.77, so Kyntra Bio's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	-43.33%
50-Day Moving Average	9.18
200-Day Moving Average	8.83
Relative Strength Index (RSI)	52.82
Average Volume (20 Days)	42,856

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kyntra Bio had revenue of $8.30 million and earned $215.65 million in profits. Earnings per share was $53.38.

Revenue	8.30M
Gross Profit	-30.35M
Operating Income	-59.16M
Pretax Income	-52.35M
Net Income	215.65M
EBITDA	-58.06M
EBIT	-59.16M
Earnings Per Share (EPS)	$53.38

Balance Sheet

The company has $117.98 million in cash and $19.47 million in debt, with a net cash position of $98.50 million or $24.35 per share.

Cash & Cash Equivalents	117.98M
Total Debt	19.47M
Net Cash	98.50M
Net Cash Per Share	$24.35
Equity (Book Value)	17.49M
Book Value Per Share	-4.21
Working Capital	97.45M

Cash Flow

In the last 12 months, operating cash flow was -$16.91 million and capital expenditures -$179,000, giving a free cash flow of -$17.09 million.

Operating Cash Flow	-16.91M
Capital Expenditures	-179,000
Free Cash Flow	-17.09M
FCF Per Share	-$4.22

Margins

Gross Margin	n/a
Operating Margin	-712.89%
Pretax Margin	-630.84%
Profit Margin	2,598.87%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kyntra Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.55%
Shareholder Yield	-1.55%
Earnings Yield	578.18%
FCF Yield	-45.82%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.

Last Split Date	Jun 17, 2025
Split Type	Reverse
Split Ratio	1:25

Scores

Kyntra Bio has an Altman Z-Score of -17.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.61
Piotroski F-Score	3